Drug intelligence / Profile preview

Quiklean

Development stage: Phase 3
Lead developer: Universal Integrated Corporation
Modality: Small Molecules
Administration: Oral

Overview

Quiklean is an oral pharmaceutical drug indicated for bowel preparation prior to colonoscopy. It is a combination drug containing sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous. These active ingredients function as saline laxatives, drawing water into the intestinal lumen through osmotic action, thereby increasing stool volume and promoting catharsis for effective bowel cleansing. It is administered in tablet form.

Brand names: Quiklean

Beyond the preview

Go deeper on Quiklean.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quiklean.

Explore the full profile